Physician profile
Luke D Pyron
NPI 1720093396
$18,095.07
in general payments reported to CMS, 2019-2025
57 companies · $2,689 in 2025
The $2,689 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,108 · 2020: $1,532 · 2021: $3,031 · 2022: $2,652 · 2023: $2,924 · 2024: $3,158 · 2025: $2,689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,771.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,752.53 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,517.94 | 2021-2025 | |
| Lilly USA, LLC | $1,322.36 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Pfizer INC. | $1,287.50 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,156.83 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Novo Nordisk INC | $1,074.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,034.77 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $897.14 | 2019-2025 | Trintellix |
| Amgen INC. | $805.58 | 2019-2024 | Otezla, Repatha, Prolia |
| Abbott Laboratories | $646.02 | 2021-2025 | Freestyle Libre |
| Janssen Pharmaceuticals, INC | $598.01 | 2019-2025 | Xarelto, Spravato |
| Otsuka America Pharmaceutical, INC. | $583.92 | 2019-2025 | Rexulti |
| Astellas Pharma US INC | $480.23 | 2019-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $354.51 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $317.63 | 2020-2024 | Verquvo, Belsomra, Dificid |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Pyron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.